Phase 1

Image of a Petri dish and pipette with sample


CD40-CD40L interaction is an attractive target for blocking T-cell–mediated B-cell–driven autoimmunity and prevention of solid organ transplant rejection. External proof-of-concept for inhibition of this pathway has been previously established in patients with a broad range of autoimmune diseases, including systemic lupus erythematosus, rheumatoid arthritis, Sjögren syndrome, liver transplant, and Graves disease.

Status: Phase 1

We are enrolling healthy subjects in a single-ascending-dose Phase 1 clinical trial. The first-in-human trial will measure safety and pharmacokinetics as well as receptor occupancy and T-cell–dependent antibody responses. Top-line data are expected in the second half of 2020.

Explore Our Pipeline

We are intent on developing an array of innovative therapies that answer the many and varied needs of patients.